Oligomerix wins $1.7M grant to support research on Alzheimer's drug candidates

09/13/2013 | Pharmaceutical Business Review Online

The NIH's National Institute on Aging awarded Oligomerix a two-year, $1.7 million grant to support its research on small molecule drugs designed to prevent tau oligomer formation, which is believed to play a key role in Alzheimer's disease progression. "This program will allow us to evaluate our lead candidates in animal models of AD and related tauopathies with the goal of selecting candidates for IND enabling studies, a prelude to initial clinical evaluation," Oligomerix President and CEO James Moe said.

View Full Article in:

Pharmaceutical Business Review Online

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Clinical Trials Agreements Specialist (209955)
The Henry M. Jackson Foundation for the Advancement of Military Medicine Inc.
Rockville, MD
SAFETY, HEALTH, and ENVIRONMENTAL (SHE) REGIONAL SPECIALIST
Matheson Tri-Gas, Inc.
Newark, CA
Catheter Engineer
ASAHI INTECC, Orange County CA R&D Center
Santa Ana, CA
MANAGER MEDICAL GAS COMPLIANCE AND SAFETY
Matheson Tri-Gas, Inc.
Houston, TX
Neurovascular Intervention Product Sales Rep, North East
ASAHI INTECC
Multiple Locations, SL_Multiple Locations